• United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options for 9,500 shares at USD 146.03 on June 9, 2026.
• Rothblatt sold 9,500 shares on June 9 at weighted-average prices ranging from USD 544.69 to USD 552.89.
• Directly owned common shares fell to 40,513 from 50,013 following the transactions.
• Stock options beneficially owned rose to 69,410 following the option exercise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000073), on June 10, 2026, and is solely responsible for the information contained therein.